Old Web
English
Sign In
Acemap
>
authorDetail
>
Jenna Mitchell
Jenna Mitchell
University of Sydney
non squamous
Durvalumab
Tremelimumab
EGFR Tyrosine Kinase Inhibitors
Chemotherapy
2
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
ENZA-p trial protocol: A randomised phase II trial using PSMA as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
2021
BJUI
Louise Emmett
Shalini Subramaniam
Anthony M. Joshua
Megan Crumbaker
Andrew J. Martin
Alison Yan Zhang
Nisha Rana
Ailsa Langford
Jenna Mitchell
Sonia Yip
Roslyn J. Francis
Michael S. Hofman
Shahneen Sandhu
Arun Azad
Craig Gedye
Margaret McJannett
Martin R. Stockler
Ian D. Davis
New Zealand Urogenital
Show All
Source
Cite
Save
Citations (1)
A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE).
2020
Journal of Clinical Oncology
Chee Khoon Lee
Shalini Subramaniam
Antony Mersiades
Jenna Mitchell
Hannora Jurkovic
Mariya Walker
Loc Le
Chris Brown
Benjamin Solomon
Thomas John
Martin R. Stockler
Bin-Chi Liao
James Chih-Hsin Yang
Chao Hua Chiu
Show All
Source
Cite
Save
Citations (1)
1